Elevated mRNA expression of SLC4A7 impedes (Figure 10D), SLC9A1 improves (Figure 9D), whereas SLC16A1 and SLC16A3 show no influence on (Figure 10—figure supplements 1D and 2D) patient survival in luminal A breast cancer. Here, SLC16A3 is linked to breast carcinoma.